多发性骨髓瘤：诊断与治疗
Multiple Myeloma: Diagnosis and Treatment.
作者信息
Rajkumar S Vincent, Kumar Shaji
机构信息
Division of Hematology, Mayo Clinic, Rochester, MN.
Division of Hematology, Mayo Clinic, Rochester, MN.
出版信息
Mayo Clin Proc. 2016 Jan;91(1):101-19. doi: 10.1016/j.mayocp.2015.11.007.
Abstract
The diagnosis and treatment of multiple myeloma has changed dramatically in the past decade. The disease definition has been updated to include highly specific biomarkers in addition to established markers of end-organ damage. The staging system has been revised to combine both measures of tumor burden and disease biology. Advances in therapy have resulted in a marked improvement in overall survival. New drugs introduced in the past few years include carfilzomib, pomalidomide, panobinostat, ixazomib, elotuzumab, and daratumumab. In this review, we outline the current approach to the diagnosis, prognosis, and management of multiple myeloma.
摘要
在过去十年中，多发性骨髓瘤的诊断和治疗发生了巨大变化。疾病定义已更新，除了既定的终末器官损伤标志物外，还纳入了高度特异性的生物标志物。分期系统已修订，以结合肿瘤负荷和疾病生物学的测量指标。治疗进展使总生存期显著改善。过去几年引入的新药包括卡非佐米、泊马度胺、帕比司他、伊沙佐米、埃罗妥珠单抗和达雷妥尤单抗。在本综述中，我们概述了多发性骨髓瘤诊断、预后和管理的当前方法。
相似文献
1
Multiple Myeloma: Diagnosis and Treatment.多发性骨髓瘤：诊断与治疗
Mayo Clin Proc. 2016 Jan;91(1):101-19. doi: 10.1016/j.mayocp.2015.11.007.
2
Myeloma today: Disease definitions and treatment advances.多发性骨髓瘤现状：疾病定义和治疗进展。
Am J Hematol. 2016 Jan;91(1):90-100. doi: 10.1002/ajh.24236.
3
The effect of novel therapies in high-molecular-risk multiple myeloma.新型疗法在高危多发性骨髓瘤中的作用。
Clin Adv Hematol Oncol. 2017 Nov;15(11):870-879.
4
How is patient care for multiple myeloma advancing?多发性骨髓瘤的患者护理是如何取得进展的？
Expert Rev Hematol. 2017 Jun;10(6):551-561. doi: 10.1080/17474086.2017.1326814. Epub 2017 May 19.
5
Emerging therapies in multiple myeloma.多发性骨髓瘤的新兴疗法
Am J Clin Oncol. 2015 Jun;38(3):315-21. doi: 10.1097/COC.0b013e3182a4676b.
6
[Current treatment of refractory and relapsed multiple myeloma].[难治性和复发性多发性骨髓瘤的当前治疗方法]
Rinsho Ketsueki. 2016;57(10):2084-2095. doi: 10.11406/rinketsu.57.2084.
7
Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.第六届海德堡骨髓瘤研讨会会议报告：多发性骨髓瘤诊断与治疗的现状及进展
J Cancer Res Clin Oncol. 2017 Dec;143(12):2521-2526. doi: 10.1007/s00432-017-2463-x. Epub 2017 Jun 26.
8
Safety issues and management of toxicities associated with new treatments for multiple myeloma.多发性骨髓瘤新型治疗相关毒性的安全性问题及管理。
Expert Rev Hematol. 2017 Mar;10(3):193-205. doi: 10.1080/17474086.2017.1284584. Epub 2017 Jan 27.
9
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.多次接受治疗的复发难治性多发性骨髓瘤患者的治疗选择
Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):460-473. doi: 10.1016/j.clml.2022.01.011. Epub 2022 Jan 19.
10
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.多发性骨髓瘤：复发和难治性疾病治疗中给药剂师的最新信息
J Oncol Pharm Pract. 2016 Apr;22(2):289-302. doi: 10.1177/1078155215572036. Epub 2015 Feb 17.
引用本文的文献
1
Impact of type 2 and steroid-Induced diabetes mellitus on prognosis in patients with multiple myeloma.2型糖尿病和类固醇诱导的糖尿病对多发性骨髓瘤患者预后的影响。
World J Surg Oncol. 2025 Aug 30;23(1):330. doi: 10.1186/s12957-025-03982-0.
2
Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.用于战斗的活体药物：嵌合抗原受体T细胞疗法综述
Int J Hematol Oncol Stem Cell Res. 2025 Apr 1;19(2):180-190. doi: 10.18502/ijhoscr.v19i2.18555.
3
Polymorphisms in Necroptosis Pathway Genes: Novel Prognostic Markers for Multiple Myeloma Treatment Outcomes.坏死性凋亡通路基因多态性：多发性骨髓瘤治疗结果的新型预后标志物
Int J Mol Sci. 2025 May 29;26(11):5237. doi: 10.3390/ijms26115237.
4
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma.埃拉纳单抗与三重耐药性多发性骨髓瘤真实世界外部对照臂的最新间接比较
Blood Lymphat Cancer. 2025 Jun 5;15:11-20. doi: 10.2147/BLCTT.S516356. eCollection 2025.
5
MAMDC2-AS1 Induces Cuproptosis in Relapsed and Refractory Multiple Myeloma.MAMDC2-AS1在复发难治性多发性骨髓瘤中诱导铜死亡
Cancer Rep (Hoboken). 2025 May;8(5):e70216. doi: 10.1002/cnr2.70216.
6
Efficacy of maintenance or consolidation therapy for multiple myeloma based on proteasome inhibitors: a meta-analysis.基于蛋白酶体抑制剂的多发性骨髓瘤维持或巩固治疗的疗效：一项荟萃分析。
Discov Oncol. 2025 Apr 12;16(1):519. doi: 10.1007/s12672-025-02304-w.
7
Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta-Analysis.达雷妥尤单抗、来那度胺和地塞米松对比硼替佐米、来那度胺和地塞米松用于不适合移植的新诊断多发性骨髓瘤：一项系统文献综述和荟萃分析
Hematol Oncol. 2025 May;43(3):e70061. doi: 10.1002/hon.70061.
8
A Randomized Controlled 'REAL-FITNESS' Trial to Evaluate Physical Activity in Patients With Newly Diagnosed Multiple Myeloma.一项评估新诊断多发性骨髓瘤患者身体活动情况的随机对照“REAL-FITNESS”试验。
J Cachexia Sarcopenia Muscle. 2025 Apr;16(2):e13793. doi: 10.1002/jcsm.13793.
9
Challenges in Multiple Myeloma Therapy in Older and Frail Patients.老年和体弱患者多发性骨髓瘤治疗中的挑战
Cancers (Basel). 2025 Mar 11;17(6):944. doi: 10.3390/cancers17060944.
10
Genetic evidence identifies a causal relationship between EBV infection and multiple myeloma risk.基因证据表明EB病毒感染与多发性骨髓瘤风险之间存在因果关系。
Sci Rep. 2025 Feb 21;15(1):6357. doi: 10.1038/s41598-025-90479-1.
本文引用的文献
1
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).SWOG S0777 随机 III 期试验的长期随访：硼替佐米、来那度胺和地塞米松与来那度胺和地塞米松治疗未经治疗的多发性骨髓瘤且无立即进行自体干细胞移植（ASCT）意向的患者。
Blood Cancer J. 2020 May 11;10(5):53. doi: 10.1038/s41408-020-0311-8.
2
Interpretation of cytogenetic results in multiple myeloma for clinical practice.多发性骨髓瘤细胞遗传学结果在临床实践中的解读
Blood Cancer J. 2015 Oct 30;5(10):e365. doi: 10.1038/bcj.2015.92.
3
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统：国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
4
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.依鲁替尼联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤的疗效和安全性：一项多中心、开放标签的 II 期研究
N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.
5
Smoldering multiple myeloma.冒烟型多发性骨髓瘤
Blood. 2015 May 14;125(20):3069-75. doi: 10.1182/blood-2014-09-568899. Epub 2015 Apr 2.
6
Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.新诊断多发性骨髓瘤患者肾功能的改善及其对生存的影响。
Blood Cancer J. 2015 Mar 20;5(3):e296. doi: 10.1038/bcj.2015.20.
7
Clinical Course and Prognosis of Non-Secretory Multiple Myeloma.非分泌型多发性骨髓瘤的临床病程及预后
Eur J Haematol. 2015 Feb 16. doi: 10.1111/ejh.12534.
8
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.老年评估可预测老年骨髓瘤患者的生存率和毒性：国际骨髓瘤工作组报告
Blood. 2015 Mar 26;125(13):2068-74. doi: 10.1182/blood-2014-12-615187. Epub 2015 Jan 27.
9
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.卡非佐米、来那度胺和地塞米松治疗复发多发性骨髓瘤。
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
10
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
Zotero 插件